Simple Summary The current review summarizes the new potential treatment strategies for
patients with early-stage non-small cell lung cancer with immunotherapy and targeted …

Lung cancer poses a significant public health challenge, with resectable non-small cell lung
cancer (NSCLC) representing 20 to 25% of all NSCLC cases, staged between I and IIIA …

The incidence of lung cancer has become the highest among all cancer types globally, also
standing as a leading cause of cancer-related deaths. Lung cancer is broadly divided into …

Background Non-small cell lung cancer (NSCLC), the most prevalent lung cancer subtype,
presents significant treatment challenges. Cisplatin (CP)-based regimens are central to the …

Neoadjuvant immune checkpoint blockade (ICB) combined with chemotherapy has
improved survival outcomes in locally-advanced non-small cell lung cancer (NSCLC) …

Results| Of 834 797 patients (53.0% male; median [IQR] age, 66 [56-76] years; race and
ethnicity, 3.7% Asian; 11.9% Black; 6.6% Hispanic; 0.6% Native and Pacific Islander; 81.8 …

Background There are limited data concerning pneumonectomy after preoperative induction
therapy. Our study aimed to evaluate feasibility and safety of pneumonectomy after …

OBJECTIVES The goal was to explore clinical factors and build a predictive model for the
disease-free and overall survival of patients with non-small cell lung cancer (NSCLC) …

Introduction Pyroptosis represents a mode of programmed necrotic cell death (PCD),
mediated by members of gasdermin family (GSDMs), such as GSDME. It is emerging as a …

The treatment of early-stage non-small cell lung cancer (NSCLC) is becoming increasingly
complex. Standard of care management for the past decade has been adjuvant …